Boston Scientific Corporation (NYSE:BSX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Boston Scientific has a consensus analyst rating of “Moderate Buy” from 27 analysts, with 23 buy ratings and an average 12-month price target of about $92.29.
• The stock has been under pressure, recently opening near $50.34 and falling 12.7%, even as the company reported a slight earnings and revenue beat in its latest quarter.
• Boston Scientific also authorized a $5 billion share repurchase program, while insiders, including two directors, bought shares recently, signaling some internal confidence despite the weaker near-term outlook.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-seven analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, twenty-three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $92.2917.

A number of equities research analysts have recently issued reports on BSX shares. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an "overweight" rating for the company in a research report on Thursday, April 23rd. Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a research report on Wednesday. Robert W. Baird cut their price objective on shares of Boston Scientific from $78.00 to $75.00 and set an "outperform" rating for the company in a research report on Tuesday, May 19th. TD Cowen cut their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. Finally, UBS Group cut their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research report on Tuesday, March 17th.

Boston Scientific Trading Down 12.7%

Shares of BSX stock opened at $50.34 on Thursday. Boston Scientific has a 1 year low of $50.04 and a 1 year high of $109.50. The firm has a fifty day moving average price of $61.13 and a 200-day moving average price of $79.19. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $74.82 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.06 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 EPS. The company's revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts predict that Boston Scientific will post 3.38 earnings per share for the current year.

Boston Scientific declared that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its shares are undervalued.

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,250 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares of the company's stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Cheryl Pegus bought 1,770 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BSX. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth $26,000. Main Street Financial Solutions LLC lifted its stake in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC lifted its stake in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC lifted its stake in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Boston Scientific cut its 2026 growth outlook and signaled softer demand in WATCHMAN and urology, raising concerns that near-term revenue growth may underdeliver versus prior expectations. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Management also highlighted competitive pressure in electrophysiology and a more cautious near-term operating backdrop, which added to investor concerns and helped trigger the stock’s sharp decline. Boston Scientific (BSX) slides after management cuts 2026 growth outlook
• Neutral Sentiment: On the positive side, Boston Scientific still has an active product pipeline, and one recent device trial reported strong efficacy, which could support the longer-term growth story if commercial adoption follows. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Neutral Sentiment: The company also deployed capital into a large private-company stake, which may appeal to long-term strategic investors but is not the main driver of the stock’s move today. Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.